Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05583149 · ClinicalTrials.gov registry record · Phase 2
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
A Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Patrick C. Johnson, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT05583149: Active Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Patrick C. Johnson, MD.
NCT05583149 is a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL) that is active but no longer recruiting, run by Patrick C. Johnson, MD. The registered enrollment target is 28 participants, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05583149, a Phase 2 study of Refractory B-Cell Non-Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma (DLBCL), is active but no longer recruiting, sponsored by Patrick C. Johnson, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Primary Outcome
The CRR is defined as the percentage of subjects achieving an objective response of complete response (CR) according to the Lugano Classification (Chesson et al., 2014), prior to start of another non-study anticancer therapy. CR is defined as a complete metabolic and radiologic response (Lugano score 1-3, target nodes/nodal masses must regress to ≤ 1.5 cm in longest diameter.)
Conditions Studied
Interventions
- DRUG Lymphodepleting chemotherapy
- DRUG ACALABRUTINIB
- DRUG LISOCABTAGENE MARALEUCEL
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Beth-Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 2 |
What the registry record for NCT05583149 still lists
NCT05583149 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 46-participant average among 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials with a reported enrollment target (39% lower).
The record links to 10 conditions, with Refractory B-Cell Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Lymphodepleting chemotherapy is the first listed.
NCT05583149 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05583149 about?
NCT05583149 is a clinical study titled "Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas". This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
What is the current status of trial NCT05583149?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2023-03-01. Estimated completion is 2029-03-01.
What conditions does trial NCT05583149 study?
This clinical trial studies the following conditions: Refractory B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, DLBCL, Nos Genetic Subtypes, EBV-Positive DLBCL, Nos.
What interventions are being tested in trial NCT05583149?
The interventions under investigation include: Lymphodepleting chemotherapy (DRUG), ACALABRUTINIB (DRUG), LISOCABTAGENE MARALEUCEL (DRUG).
Who is sponsoring clinical trial NCT05583149?
This trial is sponsored by Patrick C. Johnson, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05583149 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory B-Cell Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05583149's enrollment target sits among peer trials
28 11th of 15 higher than 5 of 15 other Refractory B-Cell Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory B-Cell Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 2
-
Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
RECRUITING · Phase 1
-
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
RECRUITING · Phase 1
-
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI